Microbix Schedules Release of Results for Q4 Fiscal 2025

Executive Summary

• Microbix Biosystems Inc. announced it will file its Q4 2025 financial statements, MD&A and results prior to market open on December 18 2025.
• A live investor webinar discussing the Q4 2025 results will be held at 10:00 AM ET on that date, featuring the CEO, CFO and COO.
• Registration details and audio/streaming links were provided for shareholders and analysts to attend or view a replay later.

Key Details

• Filing Timeline: Financial statements, management’s discussion & analysis, and results news release for Q4 2025 (ended September 30 2025) will be filed before the start of trading on December 18 2025.
• Webinar Information:
• Date & Time: December 18 2025, 10:00 AM ET
• Hosts: CEO Cameron Groome, CFO Jim Currie, COO (unnamed)
• Registration link: https://us02web.zoom.us/webinar/register/WN_uKFYZc_DTZinjJoUP46rcA
• Live‑stream on YouTube: https://www.youtube.com/channel/UC7Jpt_DWjF1qSCzfKlpLMWw
• Audio dial‑in: +1 587 328 1099 (Canada)
• Replay will be posted on Adelaide Capital’s YouTube channel.
• Company Background (retained for context): Microbix Biosystems Inc. develops and manufactures life‑science products, reported C$ 25.4 million revenue in fiscal 2024, and holds multiple regulatory accreditations (ISO 9001/13485, FDA, TGA, Health Canada, CE).
• Forward‑Looking Statements: The release contains typical forward‑looking language regarding timing of results, business outlook, risks, capital needs, etc., with no guarantee of future performance.

Notable Quotes

(No direct quotes were included in the release.)